Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 2

Tacrolimus ointment in the management of atopic dermatitis

Authors Baldo A, Cafiero, Di Caterino P, Di Costanzo

Published 27 January 2009 Volume 2009:2 Pages 1—7

DOI https://doi.org/10.2147/CCID.S3378

Review by Single-blind

Peer reviewer comments 2


Antonello Baldo, Mariana Cafiero, Paola Di Caterino, Luisa Di Costanzo

Department of Dermatology, University of Naples Federico II, Naples, Italy

Abstract: Atopic dermatitis (AD) is a chronic, relapsing, highly pruritic inflammatory skin disease. AD long-term treatment is usually required to control and prevent flares, and patients need a treatment that is safe and efficacious when applied continuously or intermittently over a prolonged period of time. The treatment options should be chosen according to age, clinical features and severity of the disease in every single patient. For the treatment of a chronic disease like AD, sustained tolerability and efficacy of the applied medications are essential. A topical immunomodulator, tacrolimus ointment, provides an alternative to topical corticosteroids without the associated adverse events. Tacrolimus is a macrolide lactone with unique immunomodulatory properties and strong anti-inflammatory activities and can be used without increasing the risk of infection or other non-application site adverse events, and without loss of effectiveness, in patients with AD.

Keywords: atopic dermatitis, tacrolimus, safety

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]